Thursday, 20 December 2018

Eli Lilly sees 2019 profit, revenue above estimates; shares rise

Eli Lilly forecast better-than-expected revenue and adjusted profit for 2019, as the drugmaker benefits from higher demand for its newer medicines including diabetes drug Trulicity and psoriasis drug Taltz.

from Earnings https://ift.tt/2AaBmWj
via IFTTT

No comments:

Post a Comment